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Abstract
Background: Bovine Leukemia Virus (BLV) produces disorders on the immune system in naturally infected animals,
which may counteract the development of immunity after vaccination. The aim of this study was to investigate
whether healthy and BLV infected cattle elicited similar humoral responses after foot and mouth disease (FMD)
immunization. In a field study, 35 Holstein heifers were selected based on their BLV serological status and immunized
with a single dose of a commercial bivalent oil-based FMD vaccine. Serum samples were collected at 0, 15, 60, 165
and 300 days post vaccination (dpv).
Results: Total anti-A24/Cruzeiro antibodies, IgM, IgG1, IgG2 titers and avidity index of specific antibodies were
determined by ELISA. Although only marginally significant differences were found between groups in terms of total
antibodies, anti-FMD IgM and IgG1 titers were significantly lower in heifers infected with BLV at the 15 dpv (p < 0.01).
Animals that became infected during the study did not show differences to the BLV negative group.
Conclusions: Cattle infected with BLV at the time of immunization may elicit a low-magnitude serological response to
a commercial Foot-and-mouth disease vaccine.
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Background
Enzootic bovine leucosis is a contagious disease of cattle
induced by an exogenous retrovirus, bovine leukemia
virus (BLV). It is worldwide distributed and only 20
countries had been able to eradicate the disease.
Approximately 60 % of infected animals do not display
clinical signs of disease, and these animals are referred to
as asymptomatic or aleukemic. Approximately 30–40 % of
BLV carriers will develop a persistent lymphocytosis, while
fewer than 5 % develop malignant lymphosarcoma [1].
BLV positive animals at early stages of infection develop
a cellular response mediated mainly by T helper 1
lymphocytes (Th1) producing IL-2, IL-12 and IFN-γ. Dis-
ease progression, together with persistent lymphocytosis
produces changes on the T-cells profile towards a Th2
response [2]. In this phase, there is a dramatic increase in
the B-lymphocyte populations and a decrease in the
percentages of both CD4+ and CD8+ T lymphocytes [3].
The altered cytokine production was suggested to be
responsible for the suppressed mitogen-induced T
lymphocyte proliferation in BLV-infected animals [3, 4].
Current literature discuses if these BLV-induced
immune mechanisms have a detrimental impact on the
ability of cattle to resist the progression of infectious
disease [5–7]. Considering that BLV is endemic in many
countries and approximately 60 % of the animals are
asymptomatic, it is important to know how BLV infec-
tion interacts with the immunogenicity of those vaccines
usually used in bovines. An early study reported a
possible impairment of immune responses against
rotavirus in BLV-positive animals [8]. Recently, Erskine
et al. [1] verified that dairy cows that were infected with
BLV had decreased antibody responses to J5 E. coli
bacterin as compared to non-infected cows.
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Foot and mouth disease (FMD) is a highly contagious
acute vesicular viral disease that affects cloven-hoofed
animals and is mainly controlled by vaccination. The cir-
culation of FMD virus (FMDV) in susceptible livestock
imposes severe restrictions on the movement and trade
of animals and derived products, causing serious eco-
nomic loss to the affected countries [9]. FMD is endemic
in many parts of Asia, Africa, and South America, where
vaccination of susceptible populations is widely used as
a major control measure. Commercial formulations
usually contain more than one virus strain, as immune
responses induced by vaccination are strain-specific [10].
Protection is mediated by specific antibodies. IgG1 has
been related with protection in vaccinated cattle [11–14]
while IgM mediates protection in naïve-infected cattle
[15]. Maintaining high levels of total antibodies against
FMDV is paramount to prevent outbreaks, keeping the
OIE free-with-vaccination status and thus, the inter-
national markets.
There is no information on how the application of
FMD vaccine in BLV infected animals may interfere with
the immune response against FMDV. Considering the
critical role that T- and B-cell populations play in
humoral immunity and the immune-modulation caused
by BLV in cattle, the purpose of this study was to inves-
tigate whether BLV natural infection may counteract the
serological response to FMD primo- vaccination.
Methods
Animals
Thirty-five animals 6 to 10 months old Heifers were
selected from a herd of 73 heifers according to their
BLV antibodies status measured by ELISA twice (4 weeks
and 1 week) before vaccination against FMD. The
animals had not received anti-FMDV vaccine until the
beginning of the experiment. They received one dose of
FMD vaccine throughout the study, corresponding to
FMD vaccination campaign of February 2014. Animals
were housed in the same farm situated in the Department
of Florida-Uruguay.
Vaccine
A commercial oil-adjuvanted (water-in-oil) vaccine against
FMD was used in this study. This is an oil-adjuvanted
vaccine that contains two inactivated FMDV strains: O1/
Campos and A24/Cruzeiro, produced by a Paraguayan
manufacturer. This vaccine was approved by the
“Ministerio de Ganadería Agricultura y Pesca” (MGAP)
according to the current national regulations of Uruguay.
Experimental design
The selected heifers were divided into 2 groups: BLV
seropositive (BLV+, n = 20) and BLV seronegative (BLV–,
n = 10). There were 5 seronegative animals at the day of
vaccination (Day 0) seroconverted throughout the study,
they were considered in a third group: Seroconverted
(SC). Furthermore, all seropositive animals were tested
by hemogram in peripheral blood mononuclear cell
(PBMC) to detect leukocytosis or lymphocytosis at the
beginning of the experiment using the protocol de-
scribed by Marshak et al. [16]. All the selected animals
were negative against anti FMDV antibodies at 0 dpv
(liquid phase blocking ELISA titers ≤ 1.5).
All animals received one dose of 3 mL of FMD vaccine
applied subcutaneously in the left side of the neck,
according to current regulation in Uruguay [17]. Serum
samples (2 aliquots of 2 mL each per animal) obtained
at 0, 15, 60, 165 and 300 dpv were stored at −20 °C for
further serological assessments.
BLV antibody detection by ELISA
A commercial kit was used for detection of BLV specific
antibodies in bovine sera (IDEXX, REF P02110-10 LOT
4155 N, The Netherlands. Samples were processed
according to manufacturer’s instructions and the reading
was performed at 450 nm in a visible range spectropho-
tometer (Thermo Fisher Scientific Inc., USA). Two weak
positive controls were used per plate and interpretation
was made according to manufacturer’s protocol.
Liquid phase blocking ELISA (LPBE)
Total anti-FMDV A24/Cruzeiro antibody responses were
assessed in serum samples by LPBE performed as stated
by the OIE Manual using a rabbit antiserum to capture
inactivated whole 140S viral particles, and a guinea-pig
antiserum as detector antibody, both of them strain-
specific as described before [18]. Antibody titers were
expressed as the reciprocal Log10 of serum dilutions giv-
ing the 50 % of the absorbance recorded in the virus
control wells without serum.
Single dilution avidity ELISA
Avidity assessment of specific antibodies was performed
at 15 dpv as described before [12]. The Avidity Index
(AI) was calculated as the percentage of residual activity
of the serum sample after a 20 min urea washing step,
relative to that of untreated sample: AI% = (OD sample
with urea/OD sample without urea) × 100.
Isotype ELISAs
Isotype ELISAs were performed as reported before
[12, 18] using HRP-conjugated antibodies anti IgG1
(1:750), IgG2 (1:750) and IgM (1:500) (AbD Serotec,
Oxford, UK). Briefly, 96 well flat bottom well plates
(MICROLON®, Greiner Bio-One, Monroe, NC) were
coated with 50 μl per well of a dilution that contained
15 ng/well of sucrose-gradient purified FMDV 146S parti-
cles of A24 Cruzeiro strain, and blocked with dilution
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buffer. Individual serum samples were run in two-fold ser-
ial dilutions starting at 1:50. Titers were expressed as the
inverse dilution reaching the cut off value (0.2) calculated
as mean OD+ 2SD achieved by the FMDV-negative
Patagonian bovine serum samples (n = 25). Titers were
expressed as the dilution factor reaching the cut-off
value [12].
Data analysis
The “expected protection percentage” (EPP) was used as
a reference to protective vaccine-induced responses. The
EPP relates antibody titers measured by LPBE at 60 dpv,
with the percentages of protection achieved for the same
groups of animals after in vivo challenge experiments
performed at 90 dpv following the “protection against
generalized foot infection” (PGP) test. LPBE titers corre-
sponding to EPP values = 75 % (EPP-75 %) are 1.90 for
A24/Cruzeiro strain [19, 20].
Time-course titers obtained by LPBE, AI and IgG-
subtype ELISAs were plotted and results between the
three experimental groups were compared by ANOVA
2-factor repeated measures followed by Bonferroni
multiple comparisons test. Mann-Whitney test was used
when data from the groups were compared. The confi-
dence interval was 95 %. Statistical analyses were carried
out using GraphPad Prism v5.0 (GraphPad Software).
Results
Total antibodies against BLV and hemogram results
Groups BLV+ and BLV- remained seropositive and
seronegative respectively, whereas the SC group
seroconverted during the study between day 15 and 150
of the experiment (Fig. 1). Any animal showed
leukocytosis or lymphocytosis at the beginning of the ex-
periment, which was confirmed by hemogram in PBMC.
Total FMDV antibodies
LPBE kinetics curves were similar between the three
groups up to day 300 of the assay. Total antibody
titers increased after vaccination in all the animals
and this difference was significant at 15 dpv for each
group compared to titers measured at 0 dpv (p <
0,01). After that, the titers decreased and remained at
low levels up to the end of the experiment. Antibody
levels fell below the EPP 75 %- protective levels for
FMD after 60 dpv (Maradei, et al. [19]) (Fig. 2a).
Total FMD LPBE titers 15 dpv were not significantly
different between groups (p > 0.05), although titers
were higher in the BLV-compared with BLV+ group
(Fig. 3a).
Avidity indexes kinetic curves were comparable
between the groups. Antibody avidity was boosted 15
dpv, and the tendency seemed to be higher for BLV-
animals, however, though differences were not signifi-
cant compared to BLV+ animals (Fig. 3e).
The SC group behaved as the BLV-animals, both for
total antibodies and avidity.
Isotype responses
We then studied the isotype composition of the induced
antibodies, to verify the primary (IgM) response and the
switch towards IgG isotypes, indicative of T-cell col-
laboration. IgM, IgG1 and IgG2 titer against A24/
Cruzeiro strain were measured in serum samples from
the different groups along time.
An increase in IgM anti-FMDV serum titers was
observed at 15 dpv in all groups, being significantly
higher in BLV negative animals (Fig. 3c). IgG1 titers
were also higher for BLV negative compared to BLV
positive animals at 15 dpv (p < 0,01), with a mean
titer of 287,1 y 127,8 respectively (Fig. 3b). At longer

























Fig. 1 Kinetics of BLV Ab titers of each group of animals throughout the study measured by indirect ELISA. Mean titers standard errors (SEM) are
depicted. BLV – and BLV+ animals were negative and positive respectively throughout the experiment. The “BLV seroconverted” group corresponds to
animals that were seronegative at the beginning of the experiment and became seropositive to BLV at 60 dpv
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detected (Fig. 2b). IgG2 titers and kinetics were
similar in all groups (Fig. 2c). Higher antibody titers
were observed at 15 dpv in BLV negative animals,
with a mean titer of 229.3 compared with 174.6 of
BLV positive animals (Fig. 3d), although this differ-
ences were not significant (p > 0,05). In all cases, the
SC group behaved as the BLV-animals in terms of
isotype responses.
Discussion
FMD has global consequences, costing an estimated
USD $6–$21 billion each year in prevention expendi-
tures and agricultural damage [9]. A significant portion
of this cost is shouldered by the world’s poorest countries,
which experience major economic losses from trade
restrictions [21]. Uruguay, a small country where the main
economy comes from agriculture and depends heavily on
the export of products of animal origin, was free from
FMD without vaccination until 2000. Later, after clinical
signs manifestations in cattle, government turned to com-
pulsory vaccination in all the country. Uruguay is actually
classified as free from FMD with vaccination and invests
millions of dollars to assure the maintenance of the FMD-
free status granted by the World Organization for Animal
Health.
On the other hand, BLV is another main virosis of
dairy cattle, produces chronic infections with high per-
centage of asymptomatic animals. BLV infection reduces
expression of type 1 cytokines from CD4+ T lympho-
cytes, and cytokine profiles from all peripheral blood
mononuclear cell populations, suggesting that both type
I and II cytokines are altered with increases in IL10 and
IL4, and decreases in IL2, IL12, and IFN-γ [5, 22]. The
progression of BLV is also known to disrupt the homeo-
stasis of lymphocyte proliferation and cell death, in both
B-cells and T-cells [1, 3, 4, 6].
Here we evaluated if the application of a bivalent FMD
vaccine in BLV infected animals modify the humoral
responses against A24/Cruzeiro strain included in the
FMD vaccine. The study was designed to assess the
FMD responses to match the practical approach applied
in the field, where the probability of heifers to be
infected with BLV at the moment of vaccination is very
high, mainly in Uruguay, where the seroprevalence may
reach 77 % in dairy cattle [23].
FMD immune response to vaccination is currently
assessed using Liquid phase blocking ELISA (LPBE), and
there are published curves relating LPBE titers with
protection. An EPP of 75 % has been estimated to cor-
respond to LPBE titers equal to 1.90 for A24/Cruzeiro
strain [19, 20]. The animals included in this study
presented low levels of antibody titers between 1.4 and
1.5 for A24/Cruzeiro at Day 0 of assay. This basal
response could be associated to maternal antibodies
transferred by colostrum because animals used were
from 6 months age [24]. Even though, this response
would not be interfering with oil emulsified vaccine
applied in this assay [25].
After vaccination, every animal seroconverted at 15
dpv, with an average titer of 1.76 and 2.12 in BLV+ and
BLV–, respectively. Although a greater response in non-
infected heifers with titers higher than 1.90 (EPP of
75 %) was observed, this difference was not significant
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Fig. 2 Kinetics of antibody titers against A24/Cruzeiro strain in BLV
seronegative (BLV-; n = 10; white circles), BLV seropositive (BLV+;
n = 20; black circles) and seroconverted groups (SC; n = 5; gray
circles). Mean titers standard errors (SEM) are depicted. A) Total
antibody measured by LPBE. a titer of 1.90 (dotted line) is
considered to be related to an EPP 75 % for A24/Cruzeiro strain.
b IgG1 and c IgG2 measured by ELISA. All animals received one
dose of a commercial bivalent FMD vaccine at 0 dpv. Titers against
A24/Cruzeiro were significantly higher in all groups at 15 dpv
compared to 0 dpv (p < 0.01)
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between groups (p > 0.05). After this period, a sharp
decrease in antibody titers in all groups was observed at
day 60, up to levels below 75 % of EPP and then
remained low until the end of the experiment (Fig. 2).
Based on these results and independently from BLV sta-
tus of heifers, the single dose vaccination applied in this
experiment was not enough to maintain animals with
acceptable levels of protective antibody titers against
FMD A24/Cruzeiro strain. Although an approved
commercial vaccine was used and applied according to
recommendations of the Uruguayan animal health
authorities, the quality of this vaccine at the exact time
it was applied could not be assessed by our working
group, in terms of antigen payload and integrity of 140S
particles, known to be essential for protection [26].
Thus, the data analyzed here correspond to the effect of
a vaccine that elicits a short coverage of circulating anti-
bodies within protective levels.
Analysis of the isotypes of the response induced
against A24/Cruzeiro revealed that IgM, IgG1 and IgG2
titers increased in both BLV-and BLV+ heifers following
FMD immunization, although IgM and IgG1 titers were
higher in the BLV negative heifers. Levels of IgG2 can
explain why the difference in antibody titers was only
marginally significant when total antibodies were
measured. On the other hand, while we found that the
avidity index was lower in seropositive animals than that











































































Fig. 3 Comparison of LPBE (a), isotypes (IgG1, (b) IgM, (c) and IgG2, (d) and avidity index (e) against A24/Cruzeiro strain for (BLV-; n = 10; white
columns), BLV seropositive (BLV+; n = 20; black columns) and seroconverted groups (SC; n = 5; gray columns) at day 15 post vaccination. Mean
titers ± standard errors (SEM) are depicted. All animals received one dose of a commercial bivalent FMD vaccine at 0 dpv. IgM and IgG1 against
A24/Cruzeiro were significantly higher in BLV – compared to BLV + at 15 dpv (p < 0.01, Mann-Whitney test)
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(Fig. 3e). The avidity index and IgM titers were
measured only 15 dpv because these decreases rapidly
according to previous reports from some researchers
from our group (Lavoria et al. [12]).
It is important to note that peak titers of both IgM and
IgG1 may not reflect, however, the true course of the
kinetics of the immune response, as many time points are
missing. Higher IgM titers have been reported to take
place about 7 to 10 dpv while IgG1 peak may be expected
at 15–20 dpv [15, 18]. Thus, we cannot rule out if we had
either a typical primary-secondary response, with a first
boost of IgM followed by a delayed increase of IgG; or if a
T-independent response was induced in both cases,
though with lower magnitude in BLV-infected animals.
We hypothesize that, if we consider the first scenario,
the immune-modulation exerted on the T lymphocytes
in BLV-infected animals may account for the lower mag-
nitude of the IgG1 anti FMDV-response. Alternations in
cytokine expression have been shown to be correlated
with disease progression in chronic retroviral infections,
suggesting that cytokine imbalances may contribute to
disease progressions [2]. Pyeon et al. [27] found that the
production of Th1 cytokine was promoted in the first
stage of the BLV infection (serologically positive without
persistent lymphocytosis) than that in cattle with
progressed disease stages with persistent lymphocytosis.
It has also been shown that IgG1 expression is positively
regulated by IL-4 and IgG2 expression is positively
regulated by IFN-gamma [28]. So, considering that the
animals used in our study were young heifers that didn’t
have persistent lymphocytosis at the beginning of the
experiment and were probably in the early phase of in-
fection (Th1 profile), we think that may have influenced
immunoglobulin subclass switch. Further experiments
are needed to support this hypothesis.
Animals that were infected with BLV between 15 to 60
dpv (“BLV seroconverted” group), did not show any
difference with respect to BLV negative animals, indicat-
ing that only a pre-existing BLV infection modified the
isotypes of antibodies against FMD induced by vaccin-
ation. This study is another contribution to the effect
that BLV may have on immunization with commonly
used vaccines. In this regard, Erskine et al. [1] also found
differences on titer of BLV antibodies in infected cows
when they were vaccinated against J5 E. coli.
Conclusions
Our data suggests that BLV infection in dairy cattle may
modify the profile of antibody response to immunization
against Foot-and-mouth disease. IgM and IgG1 titers were
significantly lower in heifers infected with BLV at the 15
dpv (p < 0.01). More studies using vaccines of different po-
tency are needed to dissect the role of BLV infection on
the efficacy of Foot-and-mouth disease primo-vaccination.
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